17.06.2013

In 2012, Russia’s pharmaceutical market was worth RUB 921bn (€22.7bn) in final consumer prices, which made it seventh among world markets, according to data from DSM group.  In comparison with 2011, the market grew by 12%. During the analysed period, 76% of drugs (by value) used in Russia were imported medicines. In the list of top pharmaceutical producers, the highest position held by a Russian company was number three, Phamstandard. The top two positions were held by foreign firms – Sanofi and Novartis. In pharmaceutical distribution, the largest company was Protek, and in retail the top spot belonged to Rigla. The commercial segment of Russia’s pharmaceutical market grew by as much as 15% in value last year, while the state-funded segment grew by only 4%.

Source: http://www.ceepharma.com